Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, toxicity and immunological effects of adjuvant administration of an
experimental therapy consisting on priming with three intramuscular administrations of a
plasmid expressing human AFP (phAFP) together with a plasmid expressing human GM-CSF
(phGM-CSF), followed by a single intramuscular boost with an AFP adenoviral vector (AdVhAFP)
to patients with locoregionally pre-treated hepatocellular carcinoma (HCC).